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Abstract
Dementia is one of the main non-motor symptoms of Parkin-
sons disease (PD) and it is diagnosed in about 30% of cases.
Its aetiology remains unclear and contributing factors are con-
troversial. Dementia may be more common in old patients with
severe motor symptoms and mild cognitive impairment. Clini-
co-pathological studies show the association between demen-
tia in PD and the age-related group of dementias, such as AD
and VaD.
A valuable aid in the assessment of dementia in PD is cerebral
blood flow (CBF) brain SPECT scanning. It shows three differ-
ent patterns of rCBF reduction, including frontal lobe hypoper-
fusion, Alzheimer-like type of hypoperfusion and multiple, vas-
cular defects. The heterogeneity of rCBF reduction may reflect
the multifactorial pathophysiology of dementia in PD. It may
result from concomitant AD pathology, cerebrovascular disease,
destruction of nigro-striato-frontal projection or may be a dis-
tinct disease of different aetiology.
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Introduction
Dementia is an acquired and persistent deterioration of the
intellect in an alert patient, with significant impairment in three or
more of the following areas: memory, language, visual-spatial skills,
mood, personality, and cognition [1, 2]. Dementia can be divided
into global dementia, when all intellectual functions are impaired,
and lacunar dementia, with more selective functional impairment.
The aetiology of dementia is complex. The large majority of de-
mentias are a result of vascular dementia (VaD) and degenerative
dementia, such as Alzheimers disease (AD), fronto-temporal de-
generation (FTD), dementia of Lewy bodies (DLB). More rare are
reversible dementias caused by symptomatic factors like vitamin
B-12 deficiency, chronic subdural haematoma, circulatory insuffi-
ciency and others.
 Dementia of Alzheimers type (DAT) and vascular dementia
(VaD) are usually considered to be the two most frequent forms of
dementia (36). Clinical and pathological studies show that ap-
proximately 5060% of cases of dementia are due to DAT, 12
20% are due to VaD, and another 1520% share neuropatholog-
ical features of both DAT and VaD [79].
The prevalence of dementia in Parkinsons disease (PD) ranges
from 10% to 95% [1012]. This wide variation is related to differ-
ences in the diagnostic criteria used or the methods adopted by
various investigators. Nevertheless, dementia in PD is seen quite
often and its aetiology remains unknown. Old age, severe motor
symptoms and mild cognitive impairment  particularly execu-
tive and visual-spatial dysfunction  are the risk factors of de-
mentia in PD [13]. Some studies suggest that bradykinesia or
masked face, but not tremor, predict the subsequent develop-
ment of dementia [14, 15].
Presumably in elderly people dementias such as AD and VaD
may be associated with PD [1621]. This may suggest a remark-
able overlap in clinical manifestation of dementia in PD, AD and
VaD. For example, dementia with Lewy bodies (DLB) comprises
features of PD and AD and is considered to be a variant of AD or
a more extended form of PD [22, 23].
Dementia has severe consequences for patients with PD, in-
cluding increased mortality and risk for nursing home placement,
as compared with non-demented patients with PD. Moreover,
dementia makes the therapeutic process more complicated, with
increased incidence of behavioural dysfunction (hallucinations or
delusions) in the course of PD [13].
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Early and accurate diagnosis of dementia in PD is essential
for: planning of appropriate medical and psychological treatment,
the identification of potentially reversible risk factors, and appro-
priate care-giver advice and intervention.
Recent attempts at treatment of cognitive symptoms in de-
mentia have largely been aimed at AD and, to some extent, VaD.
Acetylocholinesterase inhibitors (tacrine, donepezil, rivastigmine)
have emerged as the only treatment approach with demonstrable
efficacy in large-scale trials [24]. There is some evidence to sug-
gest that patients with PD and dementia may benefit from treat-
ment with cholinestererase inhibitors as well [25].
It is not clear if VaD also contribute to cognitive deterioration
in PD. Therefore, in addition to symptomatic treatment strategies,
it is essential to investigate an effective therapy of reversible causes
of dementia such as cerebrovascular risk factors (hypertension,
heart diseases, diabetes mellitus, hyperlipidaemia).
An important diagnostic tool in the investigation of dementia
in PD seems to be cerebral blood flow brain (CBF) SPECT scan-
ning. CBF SPECT scanning may detect specific patterns of rCBF
deficits associated with dementia in PD and help the clinician to
establish the diagnosis of dementia in the early stage of disease.
Most reports on CBF SPECT studies in patients with a clinical
diagnosis of PD have concluded that PD is associated with a het-
erogeneous rCBF pattern. There may be distinguished three main
subtypes of hypoperfusion in PD with dementia:
 predominantly frontal lobe type;
 posterior (Alzheimer-like) type;
 multiple small vascular defects [10, 11, 26].
Data on particular CBF changes in PD are summarised in the
table below (Table 1).
Posterior type of hypoperfusion
The perfusion defects in the temporoparietal cortex were the
most frequently found in demented patients with PD. Temporopa-
rietal hypoperfusion is considered to be the most outstanding fea-
ture of CBF alterations in AD [2833]. In demented patients with
PD a hypoperfusion nadir of 4565% was noted. On the other
hand, in non-demented patients, the nadir value was 65% [28].
Regarding cognitive functions, the scores of the Mini Mental
Score Examination show a high significant correlation with the
blood flow in temporoparietal lobe, suggesting that dementia in
PD might be caused by dysfunction of this lobe [34].
The rCBF pattern of AD found in the most demented patients
with PD suggests that the underlying pathophysiology for demen-
tia in PD may be similar to that seen in AD, or it may be due to
a concomitant AD process.
The neuropathological studies indicate that up to 60% of clin-
ically diagnosed PD patients had senile plaques and neurofibril-
lary tangles in the hippocampal area or neocortex [3538]. Fur-
thermore, the prevalence of dementia in pure PD is only 3.5%,
while in PD with AD it is about 56.3% [39].
In AD, there is a degeneration of cortical cholinergic neurones
originating in the subcortical basal nuclei of Meynert (nbM, nucle-
us basalis Meynert)  the main source of cholinergic neocortical
innervation. Decreased rCBF may be secondary to cortical hy-
pometabolism caused by damage of nbM. The same abnormali-
ties are seen in PD with dementia [40].
These data suggest that dementia in PD may represent the
onset of degeneration in a nondopaminergic neurotransmitter
system. Additional evidence for this hypothesis is the lack of
Table 1. Brain Perfusion SPECT Patterns associated with dementia in PD
Frontal hypoperfusion Temporoparietal Multiple focal defects
hypoperfusion (patchy pattern)
Pathogenesis the frontal lobe deafferentiation cortical cholinergic vascular pathology (multiple
hypothesis system degeneration cortical infarcts, single cortical
infarcts in strategic location,
small vessel diseases)
Neurotransmitters nigrostriatal dopaminergic subcortico-cortical no involvement
involved system dopaminergic, noradrenergic, or cortical cholinergic system
serotonergic, and cholinergic in concern
system
Mental status impairment of verbal fluency, global intellectual dysfunction memory problems, deficits in more
visualspatial dysfunction, assessed by total score than two cognitive domains
executive dysfunction on the MMSE, memory indicative of cortical or subcortical
(problem solving, planning impairment, language and dysfunction
abilities, generation of new calculating disability
concepts and mental sets)
Frequency* 22% 64% 14%
* Reference no. 27
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rCBF increase and mental deficit improvement, after treatment
with levo-dopa [41]. On the other hand, there was found to be
an improvement of selective cognitive impairment after levo-
dopa administration in globally non-demented patients with PD
[4244]. Presumably, different pathological mechanisms under-
lie neuropsychiatric symptoms in demented and non-dement-
ed patients with PD.
Frontal lobe type of hypoperfusion
Reduction of rCBF in the frontal lobe is considered to be the
second most common type of hypoperfusion seen in demented
PD patients [27]. Slight hypoperfusion in the frontal area was also
found in non-demented patients with PD [4547]. In contrast, the
marked frontal hypoperfusion seen in the demented group sug-
gested that alterations had occurred in the cortex or in the sub-
cortical nuclei projecting to the frontal lobes. This process could
lead to frontal hypoperfusion (the frontal lobe deafferentiation hy-
pothesis) [48]. The subcortico-frontal projections may include two
different nigro-striato-cortical loops: a motor loop and a com-
plex loop. Neurones in the rostromedial compacta of the sub-
stantia nigra project to the caudate, then connect to the frontal
association area (the complex loop); neurones in the caudo-
lateral compacta project to the putamen and then connect to the
pre-motor areas (the motor loop). The complex loop is related
to psychomotor function and motivation, while the motor loop is
related to motor function. The predominance of blood flow changes
in the frontal association cortex may reflect alterations in the com-
plex loop due to neuronal loss in the medial substantia nigra.
It has been established that frontal CBF deficit is a marker for de-
pression, and the severity of depression has been associated with the
severity of cognitive impairment in PD [4951]. The neuropathological
studies indicate that the additional dysfunction of the serotoninerergic
system may explain the development of both entities [52].
Multiple small vascular defects
In some PD patients, SPECT scanning reveals asymmetrically
distributed multifocal CBF deficits, also so-called patchy chang-
es, in about 13% of demented patients with PD [27]. These CBF
changes are considered to be the typical SPECT scanning fea-
ture of vascular dementia (VaD) [53, 54].
VaD is a complex disorder characterised by cognitive impair-
ment resulting from ischaemic or haemorrhagic stroke or from is-
chaemic-hypoxic brain lesions. Focal neurological signs sugges-
tive of cerebrovascular disease, such as hemiparesis, lower facial
weakness, hemianopia, sensory deficits, dysarthria or Babinski sign,
may accompany mental deficits. There are various types of under-
lying damage to tissue and vessels in VaD, including single or mul-
tiple infarcts that involve association and limbic cortices, small sub-
cortical infarcts disrupting cortico-subcortical circuits and white
matter lesions [55]. However, the most frequent types of lesions
are multiple lacunar infarctions of the brain (43%) [7].
The diagnosis of VaD cannot be made without neuroimaging
evidence of cerebrovascular disease (CVD). The most highly rec-
ommended forms of brain imaging in the diagnosis of VaD are CT
and MRI. CT is highly sensitive, up to 95% in severe brain ischaemia
[56]. However, rCBF brain seems to be superior to CT in the as-
sessment of perfusion in moderate ischaemia [57]. The crucial
point in the diagnosis of multi-vascular lesion using SPECT scan-
ning is the possibility of showing cortical infarctions and concom-
itant neurodegenerative diseases, especially in older patients.
Presumably, neuronal damage and loss of metabolic demand are
responsible for decrease in CBF SPECT [58].
Data on the relationship between PD and CVD are conflicting.
There are data both on prevalence of CVD increased to 27% in
PD patients and on low prevalence [59]. The associated risk fac-
tors for stroke, such as hypertension, heart disease, cigarette
smoking, diabetes mellitus, hyperlipidaemia and moderate alco-
hol consumption are found to be present in 32% of patients with
PD [60, 61].
Pathological studies have shown that vascular lesions alone
are probably unable to provoke a clear clinical syndrome of de-
mentia, but can modify the presentation or severity of any demen-
tia [62, 63]. For example, recent evidence found that the selective
loss of nbM neurones as part of early AD could perhaps be exac-
erbated by the further destruction of cholinergic neurones caused
by stroke. Possibly the destruction of cholinergic neurones can
contribute to the symptomatology of VaD.
This hypothesis may explain the beneficial effects of ChE in-
hibitors found in patients with VaD [24].
Conclusions
There are different patterns of rCBF changes revealed by
SPECT studies in demented patients with PD. This heterogeneity
may reflect the multifactorial pathophysiology of the disease:
 the hypoperfusion in the temporoparietal cortex may be due
to concomitant AD pathology or may be induced by changes
in the cholinergic system similar to AD;
 frontal lobe hypoperfusion may be related to dopaminergic
deficiency, which is responsible for the destruction of nigro-
striato-frontal projections;
 multifocal CBF deficits may suggest that CVD contribute to
dementia in PD.
Presumably, dementia in PD patients results from the overlap-
ping of the above-mentioned syndromes or is a completely dis-
tinct disease of different aetiology.
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